Lixisenatide
- Product Name
- Lixisenatide
- CAS No.
- 320367-13-3
- Chemical Name
- Lixisenatide
- Synonyms
- Lyxumia;ixisenatide;lixisenatide;Lixisenatide, >98%;Lixisenatide Acetate;Lixisenatide USP/EP/BP;Lixisenatide|Lixisenatide Acetate
- CBNumber
- CB01518519
- Molecular Formula
- C215H347N61O65S
- Formula Weight
- 4858.53
- MOL File
- 320367-13-3.mol
Lixisenatide Property
- storage temp.
- Store at -20°C
- solubility
- Water:103.0(Max Conc. mg/mL);21.2(Max Conc. mM)
- form
- Solid
- color
- White to pink
- Sequence
- H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2
- InChI
- InChI=1/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/s3
- InChIKey
- XVVOERDUTLJJHN-JXBMKTOPNA-N
- SMILES
- N([C@H](C(N[C@H](C(=O)N[C@@H](CCCCN)C(N[C@H](C(=O)N)CCCCN)=O)CCCCN)=O)CCCCN)C(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC([C@H]1N(CCC1)C(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2C=CC=CC1=2)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC1N=CNC=1)N)CO)CCSC)CCC(=O)O)CCC(O)=O)CCC(=O)O)[C@@H](C)CC)=O)CCCCN |&1:1,4,8,16,39,43,52,58,65,72,81,87,92,107,115,124,132,146,155,159,170,178,189,196,201,205,209,213,217,226,235,241,249,257,261,262,268,279,280,290,303,332,r|
- CAS DataBase Reference
- 320367-13-3
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H318Causes serious eye damage
H361Suspected of damaging fertility or the unborn child
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P281Use personal protective equipment as required.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P308+P313IF exposed or concerned: Get medical advice/attention.
P310Immediately call a POISON CENTER or doctor/physician.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- CS-5788
- Product name
- Lixisenatide
- Packaging
- 1mg
- Price
- $150
- Updated
- 2021/12/16
- Product number
- CS-5788
- Product name
- Lixisenatide
- Packaging
- 2mg
- Price
- $220
- Updated
- 2021/12/16
- Product number
- CS-5788
- Product name
- Lixisenatide
- Packaging
- 5mg
- Price
- $290
- Updated
- 2021/12/16
- Product number
- CS-5788
- Product name
- Lixisenatide
- Packaging
- 10mg
- Price
- $490
- Updated
- 2021/12/16
- Product number
- orb611442
- Product name
- Lixisenatide
- Packaging
- 5mg
- Price
- $805.8
- Updated
- 2021/12/16
Lixisenatide Chemical Properties,Usage,Production
Description
Lixisenatide injection is used to treat type 2 diabetes mellitus. Lixisenatide is used together with diet and exercise to help control your blood sugar. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist.
History
Lixisenatide (brand name Lyxumia), has been available since 2013 in many other countries. It is now the fifth GLP-1 receptor agonist to be approved in the United States.
Uses
Lixisenatide injection is used along with diet and exercise to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Lixisenatide injection is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Lixisenatide is not used instead of insulin to treat people with diabetes who need insulin. Lixisenatide injection is in a class of medications called incretin mimetics. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Lixisenatide injection also slows the emptying of the stomach and causes a decrease in appetite.
Definition
ChEBI: Lixisenatide is a forty-four membered polypeptide consisting of L-His, Gly, L-Glu, Gly, L-Thr, L-Phe, L-Thr, L-Ser, L-Asp, L-Leu, L-Ser, L-Lys, L-Gln, L-Met, L-Glu, L-Glu, L-Glu, L-Ala, L-Val, L-Arg, L-Leu, L-Phe, L-Ile, L-Glu, L-Trp, L-Leu, L-Lys, L-Asn, Gly, Gly, LPro, L-Ser, L-Ser, Gly, L-Ala, L-Pro, L-Pro, L-Ser, L-Lys, L-Lys, L-Lys, L-Lys, L-Lys, and L-Lys-NH2 residues joined in sequence. Used as an adjunct to diet and exercise for the treatment of adults with type II diabetes. It has a role as a glucagon-like peptide-1 receptor agonist, a hypoglycemic agent and a neuroprotective agent. It is a polypeptide and a peptidyl amide.
Indications
Both Adlyxin and Soliqua 100/33 are FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Soliqua 100/33 is indicated specifically in those inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.
Mechanism of action
Lixisenatide is a GLP-1 receptor agonist that works by increasing glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying.Insulin glargine works through regulation of glucose metabolism. Specifically, insulin lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Pharmacology
Lixisenatide acts as an agonist at the GLP-1 receptor. In the pancreas, this agonism results in increased glucose-stimulated insulin exocytosis by beta islet cells. This produces a reduction in blood glucose due to increased glucose uptake by tissues 1. GLP-1 receptor activation in the GI tract results in delayed gastric emptying which is thought to mediate the effects of lixisenatide on postprandial blood glucose.
Safety
The most common adverse reactions associated with lixisenatide during clinical trials were hypoglycemia, allergic reactions, nausea, nasopharyngitis, upper respiratory tract infection, and headache.
Lixisenatide Preparation Products And Raw materials
Raw materials
Preparation Products
Lixisenatide Suppliers
- Tel
- 0571-88211921 13355716090
- Sales@gotopbio.com
- Country
- China
- ProdList
- 2857
- Advantage
- 58
- Tel
- 15300650552
- info@apextide.com
- Country
- China
- ProdList
- 90
- Advantage
- 58
- Tel
- 18315779352
- 1904618300@qq.com
- Country
- China
- ProdList
- 35
- Advantage
- 58
- Tel
- 18271904430
- 1070737105@qq.com
- Country
- China
- ProdList
- 217
- Advantage
- 58
- Tel
- +86-21-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6005
- Advantage
- 61
- Tel
- 21-61263452 13641803416
- Fax
- 86-21-61263399
- ymbetter@glbiochem.com
- Country
- China
- ProdList
- 9981
- Advantage
- 64
- Tel
- 0086-21-67651709
- Fax
- 0086-21-67651705
- cfx759@hotmail.com
- Country
- China
- ProdList
- 410
- Advantage
- 57
- Tel
- 0411-62910999 13889544652
- meilunui@163.com
- Country
- China
- ProdList
- 4727
- Advantage
- 58
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- +1 (866) 930-6790
- Fax
- +1 (866) 333-9607
- info@adooq.com
- Country
- United States
- ProdList
- 2782
- Advantage
- 58
View Lastest Price from Lixisenatide manufacturers
- Product
- Lixisenatide 320367-13-3
- Price
- US $0.00-0.00/box
- Min. Order
- 1box
- Purity
- 99%
- Supply Ability
- 2000
- Release date
- 2024-10-29
- Product
- Lixisenatide 320367-13-3
- Price
- US $0.00-0.00/box
- Min. Order
- 1box
- Purity
- 99%
- Supply Ability
- 2000
- Release date
- 2024-10-29
- Product
- Lixisenatide Acetate 320367-13-3
- Price
- US $75.00-750.00/kg
- Min. Order
- 10kg
- Purity
- 0.99
- Supply Ability
- 20tons
- Release date
- 2023-11-27